Numbers and figures requested for Prelim report

2021-02-14

## 1   
## 1

##   
## These are designed for R-Studio

# Table 1 Sociodemographic characteristics of the final sample

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **N** | **%** |
| Age | Median:26 | IQR:14 - 38 |
| ***Sex*** | | |
| Female | 570 | 56.6 |
| Male | 437 | 43.4 |
| ***BMI*** | | |
| 18.5 - 24.9 | 414 | 41.1 |
| < 18.5 (Underweight) | 164 | 16.3 |
| 25 - 30 (Overweight) | 259 | 25.7 |
| > 30 (Obese) | 166 | 16.5 |
| ***Age groups*** | | |
| 5 - 14 | 248 | 24.6 |
| 15 - 29 | 339 | 33.7 |
| 30 - 44 | 218 | 21.6 |
| 45 - 64 | 156 | 15.5 |
| 65 + | 46 | 4.6 |
| ***Education Level*** | | |
| Secondary | 442 | 43.9 |
| Primary | 328 | 32.6 |
| University | 157 | 15.6 |
| No formal instruction | 53 | 5.3 |
| Doctorate | 20 | 2 |
| Other | 7 | 0.7 |
| ***Profession*** | | |
| Student | 418 | 39.5 |
| Small trader | 222 | 21 |
| Businessperson | 131 | 12.4 |
| Home-maker | 74 | 7 |
| Unemployed | 73 | 6.9 |
| Salaried worker | 60 | 5.7 |
| Retired | 35 | 3.3 |
| Other | 46 | 4.3 |
| ***Chronic conditions*** | | |
| Hypertension | 37 | 3.6 |
| Respiratory illness | 17 | 1.7 |
| Diabetes | 11 | 1.1 |
| Other | 52 | 5.1 |

# Fig. 1 Crude IgG and IgM seroprevalence



# Fig. 2 Household and geographic variation in IgG seroprevalence



# Try compound figure again



# Table 2 Population-weighted and test-adjusted seroprevalence estimates

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **n** | **Seropos.** | **Seroprevalence (95% confidence interval)** | | |
|  |  |  | **Crude** | **Weighted** | **Weighted, test-adjusted** |
| Total | 971 | 302 | 31.1% (28.3 - 34.1) | 31.3% (28.4 - 34.3) | 29.2% (24.3 - 34.1) |
| Female | 549 | 154 | 28.1% (24.5 - 32.0) | 28.0% (24.4 - 31.9) | 25.3% (20.0 - 31.2) |
| Male | 422 | 148 | 35.1% (30.7 - 39.7) | 34.6% (30.2 - 39.3) | 33.1% (27.6 - 40.5) |
| 5 - 14 | 241 | 69 | 28.6% (23.3 - 34.6) | 28.7% (23.3 - 34.7) | 26.1% (18.9 - 34.1) |
| 15 - 29 | 325 | 98 | 30.2% (25.4 - 35.4) | 30.7% (25.9 - 35.9) | 28.5% (21.4 - 35.1) |
| 30 - 44 | 212 | 69 | 32.5% (26.6 - 39.1) | 32.7% (26.7 - 39.3) | 30.8% (22.9 - 39.5) |
| 45 - 64 | 153 | 51 | 33.3% (26.4 - 41.1) | 34.1% (27.0 - 41.9) | 32.5% (22.8 - 41.8) |
| 65 + | 40 | 15 | 37.5% (24.2 - 53.0) | 39.4% (25.8 - 54.8) | 38.7% (20.5 - 55.8) |

# Fig. 3 Risk factor analysis for SARS-CoV-2 IgG seropositivity



# Fig. 4 Symptomatiticity among IgG seropositive and seronegative respondents

